Barclays’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $54.6M | Sell |
427,300
-23,500
| -5% | -$2.93M | 0.01% | 695 |
|
|
2025
Q4 | $55M | Sell |
450,800
-87,000
| -16% | -$9.98M | 0.01% | 733 |
|
|
2025
Q3 | $53.9M | Buy |
537,800
+225,300
| +72% | +$20.3M | 0.01% | 732 |
|
|
2025
Q2 | $25.9M | Sell |
312,500
-65,000
| -17% | -$5.19M | 0.01% | 989 |
|
|
2025
Q1 | $30.6M | Buy |
377,500
+118,500
| +46% | +$10.6M | 0.01% | 844 |
|
|
2024
Q4 | $23.3M | Buy |
259,000
+56,500
| +28% | +$5.47M | 0.01% | 1041 |
|
|
2024
Q3 | $20M | Sell |
202,500
-455,000
| -69% | -$44.7M | 0.01% | 1065 |
|
|
2024
Q2 | $61M | Buy |
657,500
+349,900
| +114% | +$31.4M | 0.02% | 558 |
|
|
2024
Q1 | $29.2M | Sell |
307,600
-372,500
| -55% | -$34.6M | 0.01% | 831 |
|
|
2023
Q4 | $60.7M | Buy |
+680,100
| New | +$50.5M | 0.02% | 584 |
|
|
2023
Q2 | – | Sell |
-202,000
| Closed | -$15.4M | – | 5130 |
|
|
2023
Q1 | $15.4M | Sell |
202,000
-38,900
| -16% | -$3.23M | 0.01% | 969 |
|
|
2022
Q4 | $20M | Buy |
+240,900
| New | +$19.5M | 0.01% | 891 |
|
|
2022
Q3 | – | Sell |
-148,500
| Closed | -$11M | – | 5175 |
|
|
2022
Q2 | $11M | Buy |
+148,500
| New | +$11.1M | 0.01% | 972 |
|
|
2022
Q1 | – | Sell |
-519,500
| Closed | -$58.2M | – | 5694 |
|
|
2021
Q4 | $58.2M | Buy |
519,500
+90,400
| +21% | +$10.9M | 0.02% | 523 |
|
|
2021
Q3 | $53.9M | Buy |
429,100
+74,000
| +21% | +$9.53M | 0.02% | 491 |
|
|
2021
Q2 | $48.1M | Sell |
355,100
-9,700
| -3% | -$1.28M | 0.02% | 536 |
|
|
2021
Q1 | $49.5M | Buy |
+364,800
| New | +$54.6M | 0.03% | 449 |
|
|
2020
Q4 | – | Sell |
-172,500
| Closed | -$19.2M | – | 5182 |
|
|
2020
Q3 | $19.2M | Buy |
172,500
+170,000
| +6,800% | +$19.1M | 0.01% | 764 |
|
|
2020
Q2 | $280K | Sell |
2,500
-181,100
| -99% | -$17.8M | ﹤0.01% | 3810 |
|
|
2020
Q1 | $14.2M | Buy |
183,600
+88,100
| +92% | +$7.8M | 0.01% | 804 |
|
|
2019
Q4 | $9.08M | Sell |
95,500
-61,100
| -39% | -$5.29M | 0.01% | 1473 |
|
|
2019
Q3 | $11.9M | Sell |
156,600
-135,900
| -46% | -$11.3M | 0.01% | 1175 |
|
|
2019
Q2 | $25.7M | Sell |
292,500
-18,900
| -6% | -$1.61M | 0.02% | 796 |
|
|
2019
Q1 | $28.2M | Sell |
311,400
-213,400
| -41% | -$18.2M | 0.02% | 674 |
|
|
2018
Q4 | $37.7M | Buy |
524,800
+289,400
| +123% | +$23.3M | 0.03% | 476 |
|
|
2018
Q3 | $22.6M | Sell |
235,400
-77,800
| -25% | -$7.54M | 0.02% | 784 |
|
|
2018
Q2 | $29.8M | Buy |
313,200
+62,100
| +25% | +$5.71M | 0.03% | 585 |
|
|
2018
Q1 | $22M | Sell |
251,100
-454,000
| -64% | -$41.4M | 0.02% | 800 |
|
|
2017
Q4 | $59.8M | Buy |
705,100
+400,400
| +131% | +$33.5M | 0.05% | 333 |
|
|
2017
Q3 | $26.4M | Sell |
304,700
-781,200
| -72% | -$62.6M | 0.03% | 547 |
|
|
2017
Q2 | $83.8M | Buy |
1,085,900
+877,000
| +420% | +$62.2M | 0.09% | 171 |
|
|
2017
Q1 | $14.5M | Sell |
208,900
-119,300
| -36% | -$8.01M | 0.02% | 690 |
|
|
2016
Q4 | $19.4M | Buy |
328,200
+66,100
| +25% | +$4.08M | 0.02% | 615 |
|
|
2016
Q3 | $17.4M | Sell |
262,100
-208,900
| -44% | -$12.9M | 0.02% | 608 |
|
|
2016
Q2 | $25.5M | Sell |
471,000
-620,200
| -57% | -$34M | 0.03% | 422 |
|
|
2016
Q1 | $55.7M | Buy |
1,091,200
+913,100
| +513% | +$47.4M | 0.08% | 189 |
|
|
2015
Q4 | $12.5M | Sell |
178,100
-209,900
| -54% | -$14.3M | 0.02% | 782 |
|
|
2015
Q3 | $24.1M | Buy |
388,000
+158,500
| +69% | +$12.5M | 0.03% | 516 |
|
|
2015
Q2 | $19.3M | Buy |
229,500
+106,800
| +87% | +$8.31M | 0.02% | 669 |
|
|
2015
Q1 | $9.2M | Buy |
122,700
+69,300
| +130% | +$4.84M | 0.01% | 1125 |
|
|
2014
Q4 | $3.31M | Sell |
53,400
-43,800
| -45% | -$2.5M | ﹤0.01% | 2068 |
|
|
2014
Q3 | $5.02M | Buy |
97,200
+77,400
| +391% | +$3.95M | ﹤0.01% | 1773 |
|
|
2014
Q2 | $1.01M | Sell |
19,800
-17,400
| -47% | -$785K | ﹤0.01% | 3334 |
|
|
2014
Q1 | $1.76M | Buy |
37,200
+14,700
| +65% | +$752K | ﹤0.01% | 2670 |
|
|
2013
Q4 | $975K | Buy |
22,500
+17,400
| +341% | +$720K | ﹤0.01% | 3424 |
|
|
2013
Q3 | $219K | Buy |
5,100
+1,200
| +31% | +$48.6K | ﹤0.01% | 4956 |
|
|
2013
Q2 | $136K | Buy |
+3,900
| New | +$137K | ﹤0.01% | 5535 |
|
Other funds holding XBI
JFG
Barclays's XBI Position: Q1 2026 in Review
Barclays increased its State Street SPDR S&P Biotech ETF (XBI) stake by 50% in Q1 2026, buying an estimated $118M and bringing the position to 2,834,160 shares worth $362M. The position accounts for 0.09% of the portfolio, ranked #166.
Barclays first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $571M in Q2 2020. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Barclays held 2,834,160 shares of State Street SPDR S&P Biotech ETF worth $362M as of Q1 2026.
- Barclays bought 943,752 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $118M.
- State Street SPDR S&P Biotech ETF made up 0.09% of Barclays's portfolio in Q1 2026, its #166 holding.
- Barclays first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
- Barclays's State Street SPDR S&P Biotech ETF position peaked at $571M in Q2 2020.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.